⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 2, 2024

Supplementary Figure S1 from Enhanced Antipediatric Sarcoma Effect of Everolimus with Secukinumab by Targeting IL17A

Dan Huang Zhipeng Wu Zhengyi Wu Nuoya Li Liang Hao Kuangfan Li Junquan Zeng Bingbing Qiu Shouhua Zhang Jinlong Yan

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S1 shows the humanization status of the PDX model detected by PCR, and HE staining and immunohistochemistry of patient’s RMS tissue and the P3 PDX model.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Huang et al. (2024) studied this question.

synapsesocial.com/papers/68e6be8ab6db64358763e210 https://doi.org/10.1158/1535-7163.25735591.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Enhanced Antipediatric Sarcoma Effect of Everolimus with Secukinumab by Targeting IL17A2024
2Supplementary Figure S2 from Enhanced Antipediatric Sarcoma Effect of Everolimus with Secukinumab by Targeting IL17A2024
3Supplementary Figure S2 from Enhanced Antipediatric Sarcoma Effect of Everolimus with Secukinumab by Targeting IL17A2024
4Supplementary Figure S3 from Enhanced Antipediatric Sarcoma Effect of Everolimus with Secukinumab by Targeting IL17A2024
5Supplementary Figure S3 from Enhanced Antipediatric Sarcoma Effect of Everolimus with Secukinumab by Targeting IL17A2024

Data from Enhanced Antipediatric Sarcoma Effect of Everolimus with Secukinumab by Targeting IL17A2024
Supplementary Figure 11 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models2024
Supplementary Figure 11 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models2024